BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma
read more...
Jun 21, 2022
BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab
read more...
Jun 13, 2022
BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets
read more...
Jun 13, 2022
BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL
read more...
Jun 10, 2022
China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer
read more...
Jun 10, 2022
BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress
read more...
Jun 08, 2022
BeiGene to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
read more...
May 26, 2022
BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio
read more...
May 17, 2022
BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland
read more...
May 12, 2022
BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress
read more...
May 05, 2022
BeiGene Reports First Quarter 2022 Financial Results
read more...
May 04, 2022
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
read more...
Apr 29, 2022
BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey
read more...
Apr 28, 2022
BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenström’s Macroglobulinemia
read more...
Apr 27, 2022
BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting
read more...
Apr 27, 2022
Global Phase 3 Trial of BeiGene’s PD-1 Inhibitor, Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma
read more...
Apr 26, 2022
BeiGene Introduces Global Environmental, Social, and Governance Strategy
read more...
Apr 21, 2022
BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Cancer Patients and Communities in New Jersey
read more...
Apr 19, 2022
BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series
read more...
Apr 15, 2022
China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma
read more...
